Event-free survival (EFS) and patient-reported outcomes (PROs) in MATTERHORN: a randomised, Phase 3 study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) chemotherapy in resectable gastric/gastroesophageal junction (G/GEJ) adenocarcinoma
Möhler, M., Al-Batran, S., Wainberg, Z., Muro, K., Molena, D., Van Cutsem, E.,… Tabernero, J., Janjigian, Y. (2026). Event-free survival (EFS) and patient-reported outcomes (PROs) in MATTERHORN: a randomised, Phase 3 study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) chemotherapy in resectable gastric/gastroesophageal junction (G/GEJ) adenocarcinoma. Oncology Research and Treatment, 49, 209-209. (Meeting abstract)
Deixa un comentari